Advagen Pharma Ltd has received FDA approval for its Abbreviated New Drug Application (ANDA090279) to market buprenorphine hydrochloride tablets for sublingual use, expanding the Therapeutic Alternatives (TA) anti-addiction portfolio. This approval grants Advagen the rights to produce and distribute the product, allowing the company to capitalize on the ongoing U.S. economic opportunity within the opioid addiction market.